- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Nanjing King-Friend Biochemical PharmaceuticalLtd
Market Cap: CN¥15.2b
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707
CN¥9.40
7D
4.1%
1Y
-22.0%
Pacific Shuanglin Bio-pharmacy
Market Cap: CN¥13.7b
Engages in research, development, production, and sales of blood products in China and internationally.
000403
CN¥14.38
7D
5.0%
1Y
-9.4%